

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/925,671	08/09/2001	Bo Arthur Einar Tjellstrom	11133Z	3329
7590 02/23/2004			EXAMINER	
•	OTT, MURPHY & PR	ROARK, JESSICA H		
400 Garden City Plaza Garden City, NY 11530			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 02/23/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	A	Applicant(s)				
	Application No.					
Advisory Action	09/925,671	TJELLSTROM ET AL.				
-	Examiner	Art Unit				
	Jessica H. Roark	1644				
The MAILING DATE of this communication appears on the cover sheet with the c rrespondence address						
THE REPLY FILED 06 February 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires 3 months from the mailing date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.136(a). The fee have been filed in the period of the fee have been filed in the filed in the feet and fil	of extension and the corresponding amoust the shortened statutory period for reply ce later than three months after the mai	ount of the fee. The appropriate extension originally set in the final Office action; or				
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) ☐ they raise the issue of new matter (see Note below);						
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
<ul><li>(d)  they present additional claims without canceling a corresponding number of finally rejected claims.</li><li>NOTE:</li></ul>						
3. Applicant's reply has overcome the following rejection(s): See Continuation Sheet.						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. ☐ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:		_				
Claim(s) allowed:	PHULPC					
Claim(s) objected to:	PHILLIP GAMI PRIM <u>ar</u> y ex	•				
Claim(s) rejected: <u>1-10,13 and 15</u> .	neu	COURTH CO				
Claim(s) withdrawn from consideration: 11 and 12.		2/19/04				
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)						
10. Other:						
		•				

Continuation of 3. Applicant's reply has overcome the following rejection(s):

the proposed amendment has obviated the previous rejection of claims 1-10 under 35 U.S.C. 102(e) as being anticipated by Salfeld et al. (U.S. Pat. No. 6,509,015, of record) by requiring that the antibody preparation be a pooled human polyclonal immunoglobulin preparation

Continuation of 5. does NOT place the application in condition for allowance because:

the proposed amendment after final "re-adds" the "pooled human polyclonal" limitation that was present in the claims when first considered on the merits (see Office Action mailed 6/2/03). Newly added claim 15 adds the requirement that the preparation be "non-antigen specific". The rejection under 35 U.S.C. 103(a) as being unpatentable over Hassig (U.S. Pat. No. 4.676,982, of record) and Hardie (U.S. Pat. No. 4,477,432, IDS) (originally set forth in the paper mailed 6/2/03 and maintained in the final rejection mailed 11/20/03) applies to the amended and newly added claims for the reasons of record, and because the immunoglobulin preparation of Hassig is non antigen specific.

#### **RESPONSE UNDER 37 CFR § 1.116** EXPEDITED PROCEDURE **EXAMINING GROUP 1644**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: B. Tjellstrom, et al.

Examiner:

Jessica H. Roark

Serial No.:

09/925,671

Art Unit:

1644

Filed:

August 9, 2001

Docket:

11133z

For: ORAL IMMUNOGLOBULIN

Dated:

February 6, 2004

TREATMENT FOR INFLAMMATORY **BOWEL DISEASE** 

Confirmation No.: 3329 Commissioner for Patents

Alexandria, VA 22313-1450

#### AMENDMENT UNDER 37 C.F.R. § 1.116

Sir:

In response to the Office Action dated November 20, 2003, and in accordance with the provisions of 37 C.F.R. §1.116, Applicants respectfully request entry of the following amendments in the above-identified case.

## CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Dated: February 6, 2004

H:\work\030\11133Z\AMEND\11133z.amn2.doc